Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review.

Introduction: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazilian regulatory agency - ANVISA.

Aim: This narrative review was conducted to review the general concepts regarding P-CABs, focussing on vonoprazan fumarate.

Real world data study of prevalence and direct costs related to dengue management in Brazil's private healthcare from 2015 to 2020.

Background: The burden of dengue in Brazil is poorly documented and is based on data from the public health care setting. This study estimated the prevalence and costs of dengue management in the private health care system in Brazil from 2015 to 2020 using a large claims database from Orizon.

Methods: We selected claims with dengue ICD codes (ICD-10 A90 or A91) from January 2015 to December 2020.

Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.

Background: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBDs) with a remission-relapsing presentation and symptomatic exacerbations that have detrimental impacts on patient quality of life and are associated with a high cost burden, especially in patients with moderate-to-severe disease. The Real-world Data of Moderate-to-Severe Inflammatory Bowel Disease in Brazil (RISE BR) study was a noninterventional study designed to evaluate disease control, treatment patterns, disease burden and health-related quality of life in patients with moderate-to-severe active IBD. We report findings from the prospective follow-up phase of the RISE BR study in patients with active UC or CD.